英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：

asquint    
a.
ad. 斜眼

斜眼

asquint
adj 1: (used especially of glances) directed to one side with or
as if with doubt or suspicion or envy; "her eyes with
their misted askance look"- Elizabeth Bowen; "sidelong
glances" [synonym: {askance}, {askant}, {asquint}, {squint},
{squint-eyed}, {squinty}, {sidelong}]


请选择你想看的字典辞典：
单词字典翻译
asquint查看　asquint　在百度字典中的解释百度英翻中〔查看〕
asquint查看　asquint　在Google字典中的解释Google英翻中〔查看〕
asquint查看　asquint　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • NTRK Fusion in Non-Small Cell Lung Cancer: Diagnosis, Therapy, and TRK . . .
    The detection of NTRK gene fusion is recommended by the National Comprehensive Cancer Network (NCCN) clinical practice guidelines, and the TRK inhibitors (larotrectinib and entrectinib) are preferred as the first-line treatment for locally advanced or metastatic patients with NTRK-fusion-positive NSCLC (8)
  • Connecting the Dots: NTRK-driven lung cancer
    For NTRK-positive lung cancer patients, the results were encouraging, with many experiencing rapid and durable responses As progress continued, attention turned to resistance In 2021, Dr Drilon and Dr Emiliano Cocco identified a new resistance mechanism publishing their findings in prestigious Nature Medicine
  • NTRK and Lung Cancer - American Lung Association
    NTRK is an important biomarker that can impact lung what treatment options Dr Robert Doebele explains what an NTRK gene fusion is in cancer NTRK is an important biomarker that can impact lung what treatment options The videos above were produced in 2020 For the latest treatment options, speak with your doctor
  • NTRK Fusion-positive Non–small-cell Lung . . . - Clinical Lung Cancer
    In cases of non–small-cell lung cancer (NSCLC), molecular-targeted therapy has shown remarkable improvements in the survival and safety compared with conventional chemotherapy Recently, the tropomyosin receptor kinase (TRK) inhibitors entrectinib and larotrectinib were approved in the United States, Europe, and elsewhere for patients with a neurotrophic tropomyosin-related kinases (NTRK
  • What is NTRK positive (NTRK+) Lung Cancer?
    If you have non-small cell lung cancer and your tumor tested positive for the NTRK biomarker, you have NTRK+ (NTRK positive) lung cancer This fact sheet explains what this means and how it may affect lung cancer treatment WHAT IS NTRK? NTRK (neurotrophic tyrosine receptor kinase) is a gene that can can move or fuse to another gene
  • NTRK gene fusion testing and management in lung cancer
    This review highlights the importance of testing for NTRK gene fusions in lung cancer, ideally using the gold-standard method of RNA-based NGS, the various assays that are available, and treatment algorithms for patients
  • FDA Approves Larotrectinib for Adult and Pediatric Patients With NTRK . . .
    FDA Approves Larotrectinib for Adult and Pediatric Patients With NTRK Gene Fusion-Positive Solid Tumors April 11, 2025
  • Systematic review of NTRK 1 2 3 fusion prevalence pan-cancer . . . - Nature
    Only 35 6% of extracted estimates used appropriate methods and sample size to identify NTRK fusions NTRK fusion-positive cancers are rare and widely distributed across solid tumours
  • Exploring the Prospects of HER2-Directed Therapies for Patients With . . .
    HER2 has recently emerged as an actionable oncogenic driver in a small but clinically meaningful subset of patients with advanced non–small cell lung cancer, with agents such as trastuzumab deruxtecan and zongertinib demonstrating efficacy and receiving scattered regulatory approvals In order to ensure equitable access to HER2-directed therapies for this population, discrepancies across
  • Non-small cell lung cancer research: advances and persistent challenges
    In fi ALK-positive cancer, lorlatinib sets a new benchmark for long-term disease control (3, 20) Targets such as KRAS G12C, METex14, and NTRK fusions now have effective inhibitors, enabling tumor-agnostic treatment approaches in some cases (28, 44) However, the durability of these responses is universally challenged by acquired resistance





中文字典-英文字典  2005-2009